Samuel Joseph Paul Malkin (Samuel J P Malkin, Samuel Malkin, S J P Malkin, Samuel Jp Malkin)

Publication Activity (10 Years)

Years Active: 2018-2023
Publications (10 Years): 10

Top Topics

Health Promotion

Glycemic Control

Cardiovascular Risk Factors

Top Venues

Diabetes, obesity & metabolism

Diabetes therapy : research, treatment and education of diabetes and related disorders

Diabetology & metabolic syndrome

This page only lists publications with an associated author ORCID identifier.

Publications

Hongye Ren, Sasha Berry, Samuel Joseph Paul Malkin, Barnaby Hunt, Stephen Bain
Early use of oral semaglutide in the UK: A cost-effectiveness analysis versus continuing metformin and SGLT-2 inhibitor therapy. BMJ open 13 (9) (2023)
Lyndon Marc Evans, Sasha Berry, Avideh Nazeri, Samuel Joseph Paul Malkin, Donna Ashley, Barnaby Hunt, Stephen C Bain
The challenges and pitfalls of incorporating evidence from cardiovascular outcomes trials in health economic modelling of type 2 diabetes. Diabetes, obesity & metabolism (2022)
Samuel Joseph Paul Malkin, Davide Carvalho, Catarina Costa, Vasco Conde, Barnaby Hunt
The long-term cost-effectiveness of oral semaglutide versus empagliflozin and dulaglutide in Portugal. Diabetology & metabolic syndrome 14 (1) (2022)
Josep Franch-Nadal, Samuel Joseph Paul Malkin, Barnaby Hunt, Virginia Martín, María Gallego Estébanez, Josep Vidal
The Cost-Effectiveness of Oral Semaglutide in Spain: A Long-Term Health Economic Analysis Based on the PIONEER Clinical Trials. Advances in therapy 39 (7) (2022)
Lyndon Marc Evans, Barrie Chubb, Samuel Joseph Paul Malkin, Sasha Berry, Jack Lawson, Barnaby Hunt
Once-weekly semaglutide versus insulin aspart for the treatment of type 2 diabetes in the UK: A long-term cost-effectiveness analysis based on SUSTAIN 11. Diabetes, obesity & metabolism (2022)
Margareta Hellgren, Ann-Marie Svensson, Stefan Franzén, Åsa Ericsson, Soffia Gudbjörnsdottir, Nils Ekström, Rebecka Bertilsson, William Valentine, Samuel Joseph Paul Malkin
The burden of poor glycaemic control in people with newly diagnosed type 2 diabetes in Sweden: A health economic modelling analysis based on nationwide data. Diabetes, obesity & metabolism 23 (7) (2021)
Johan Jendle, M I Buompensiere, A L Holm, S de Portu, Samuel Joseph Paul Malkin, O Cohen
The Cost-Effectiveness of an Advanced Hybrid Closed-Loop System in People with Type 1 Diabetes: a Health Economic Analysis in Sweden. Diabetes therapy : research, treatment and education of diabetes and related disorders 12 (11) (2021)
Johan H Jendle, Åsa Ericsson, Bertil Ekman, Stefan Sjöberg, Jens Gundgaard, João da Rocha Fernandes, Ann-Charlotte Mårdby, Barnaby Hunt, Samuel Joseph Paul Malkin, Maria Thunander
Real-world cost-effectiveness of insulin degludec in type 1 and type 2 diabetes mellitus from a Swedish 1-year and long-term perspective. Journal of medical economics 23 (11) (2020)
Russell Drummond, Samuel Joseph Paul Malkin, Michelle Du Preez, Xin Ying Lee, Barnaby Hunt
The management of type 2 diabetes with fixed-ratio combination insulin degludec/liraglutide (IDegLira) versus basal-bolus therapy (insulin glargine U100 plus insulin aspart): A short-term cost-effectiveness analysis in the UK setting. Diabetes, obesity & metabolism 20 (10) (2018)
Adie Viljoen, Christina S Hoxer, Pierre Johansen, Samuel Joseph Paul Malkin, Barnaby Hunt, Stephen C Bain
Evaluation of the long-term cost-effectiveness of once-weekly semaglutide versus dulaglutide for treatment of type 2 diabetes mellitus in the UK. Diabetes, obesity & metabolism 21 (3) (2018)